X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
RRx-001 (nibrozetone) is a multifaceted small molecule inflammasome NLRP3/KEAP1 inhibitor with tumor-targeted cytotoxicity and healthy tissue cytoprotective properties, which is investigated for the treatment of small cell lung cancer.
Lead Product(s): RRx-001,Cisplatin
Therapeutic Area: Oncology Product Name: RRx-001
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 06, 2023
Details:
RRx-001 is a highly selective NLRP3 inhibitor with vascular normalization and tumor associated macrophage polarization properties that resensitizes tumors to previously administered therapies. It is under investigation SCLC, head and neck cancer.
Lead Product(s): RRx-001
Therapeutic Area: Immunology Product Name: RRx-001
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 29, 2023
Details:
RRx-001 plus opdivo (nivolumab) as a combinaton is being investigated for advanced checkpoint inhibitor non-responsive tumors, where RRx-001 is a highly selective NLRP3 inhibitor and nivolumab monoclonal antibody that targets the anti-PD1 receptor.
Lead Product(s): RRx-001,Nivolumab
Therapeutic Area: Oncology Product Name: RRx-001
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 15, 2023
Details:
RRx-001 is a highly selective NLRP3 inhibitor with vascular normalization and tumor associated macrophage polarization properties that resensitizes tumors. RRx-001 is under investigation for SCLC and for protection against oral mucositis in first line head and neck cancer.
Lead Product(s): RRx-001,Irinotecan Hydrochloride,Bevacizumab
Therapeutic Area: Oncology Product Name: RRx-001
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 20, 2023
Details:
RRx-001 is a highly selective NLRP3 inhibitor with vascular normalization and tumor associated macrophage polarization properties that resensitizes tumors to previously administered therapies. It is under investigation SCLC, head and neck cancer.
Lead Product(s): RRx-001,Cisplatin
Therapeutic Area: Gastroenterology Product Name: RRx-001
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 19, 2023
Details:
RRx-001 is a highly selective NLRP3 inhibitor with vascular normalization and tumor associated macrophage polarization properties that resensitizes tumors to previously administered therapies.
Lead Product(s): RRx-001,Regorafenib,Bevacizumab
Therapeutic Area: Oncology Product Name: RRx-001
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 14, 2022
Details:
The potential of RRx-001 as a radiation protection agent is related to evidence of NLRP3 inflammasome inhibition and Nrf2 activation, reducing the toxicity of radiation through the suppression of inflammation, free radical and oxidative stress.
Lead Product(s): RRx-001,Cisplatin
Therapeutic Area: Gastroenterology Product Name: RRx-001
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 06, 2022
Details:
FightMND to evaluate the potential neuroprotective benefits of the company's lead small molecule, RRx-001. RRx-001, a direct NLRP3 inflammasome inhibitor, will be evaluated as a novel disease modifying therapy for MND.
Lead Product(s): RRx-001
Therapeutic Area: Neurology Product Name: RRx-001
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: FightMND
Deal Size: $0.5 million Upfront Cash: Undisclosed
Deal Type: Funding November 29, 2022
Details:
RRx-001, a direct NLRP3 inflammasome inhibitor, will be evaluated for its potential to reduce or reverse the pathological features and hallmark symptoms of PD.
Lead Product(s): RRx-001
Therapeutic Area: Neurology Product Name: RRx-001
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Michael J. Fox Foundation
Deal Size: $0.5 million Upfront Cash: Undisclosed
Deal Type: Funding July 12, 2022
Details:
RRx-001 leads EpicentRx's CyNRGY platform as a first-in-class investigational treatment sourced from an exclusively licensed portfolio of aerospace-derived small molecules.
Lead Product(s): RRx-001,Cisplatin
Therapeutic Area: Gastroenterology Product Name: RRx-001
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Dana-Farber Cancer Institute
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
